HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor • MC Services corporate website
7570
post-template-default,single,single-post,postid-7570,single-format-standard,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,client-news,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

12 May HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

Posted at 08:16h in Client News by